








Jornal de Pediatria

www.jpmed.com.br



ORIGINAL ARTICLE

Risk factors for colonization/infection by resistant microorganisms in outbreaks in neonatal unit—a systematic review and meta-analysis

Q1
Q2 Roberta Maia de Castro Romanelli ¹ ^{a,b}, Gabriela Gomes de Souza ¹ ^{c,*},
José Henrique Paiva Rodrigues ¹ ^c, João Pedro Ribeiro Viana ¹ ^c,
Kelvin Oliveira Rocha ¹ ^b, Briana Henriques Machado Tarabai ¹ ^b,
Lêni Márcia Anchieta ¹ ^{a,b}

^a Universidade Federal de Minas Gerais, Departamento de Pediatria, Belo Horizonte, MG, Brazil

^b Universidade Federal de Minas Gerais, Hospital de Clínicas, Belo Horizonte, MG, Brazil

^c Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Received 14 July 2024; accepted 12 December 2024

Available online xxx

KEYWORDS

Newborn;
Drug resistance;
Antibacterial agents;
Sepsis;
Risk factor

Abstract

Objective: This study aims to evaluate risk factors for infection/colonization by resistant bacteria among patients in Neonatal Intensive Care Units (NICU).

Methods: This systematic review is reported according to PRISMA. The search occurred by consulting the PubMed, Embase, Cochrane, SciELO, and Scopus databases. Inclusion criteria considered studies with Neonatal population admitted to the Neonatal Intensive Care Unit (P); Risk factors for resistant bacterial infection (E); No risk factors for resistant bacterial infection (C); Isolation of resistant bacteria in an outbreak (O), Observational studies (S). For Meta-Analysis, data were transformed to a logarithmic scale to directly calculate the standard error from the confidence intervals. The quality of studies was assessed Critical Appraisal Tools recommended by JBI.

Results: A total of 21 articles were eligible and presented a sample size ranging from 10 to 263 newborns (a total of 1979 neonates). Six (28,6%) studies evaluated infection, five (23,8) evaluated colonization, and 10 (47,6%) evaluated colonization and infection, covering Gram-positive ($n = 8$; 38%) and Gram-negative ($n = 13$; 62%) bacteria. In the meta-analysis, the use of venous access (OR: 1,58; 95%CI 1,14–2,20), mechanical ventilation (OR: 7,55 95%CI 4,27–13,36), and parenteral nutrition (OR: 4,79; 95%CI 2,23–10,29) increased the chance of colonization/infection by multiresistant microorganisms. The included studies were considered as having adequate quality.

Conclusion: The main risk factors in outbreaks of infection/colonization by resistant microorganisms in Neonatal Units are the use of invasive devices and parenteral nutrition, which leads

* Corresponding author.

E-mail: gabrielagomesds28@gmail.com (G.G. de Souza).

<https://doi.org/10.1016/j.jpmed.2024.12.005>

0021-7557/© 2025 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article in press as: R.M. Romanelli, G.G. de Souza, J.H. Rodrigues et al., Risk factors for colonization/infection by resistant microorganisms in outbreaks in neonatal unit—a systematic review and meta-analysis, *Jornal de Pediatria* (2025), <https://doi.org/10.1016/j.jpmed.2024.12.005>

to the identification of newborns at risk, targeting the development of preventive measures.
 © 2025 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1 Introduction

2 Healthcare-Associated Infections (HAIs) are important con-
 3 ditions among the newborn population: 30 out of every 100
 4 newborns are affected by them. In Brazil, it is estimated
 5 that 60% of infant mortality occurs in the neonatal period,
 6 and neonatal sepsis is one of the main causes.¹ Furthermore,
 7 there is evidence of an increase in neonatal infections
 8 caused by bacteria resistant to antimicrobials, which make
 9 these infections even more severe, with a higher mortality
 10 rate than infections caused by susceptible bacteria.^{2,3}
 11 Therefore, the relevance of studies that aim to mitigate
 12 neonatal infections caused by microorganisms resistant to
 13 antimicrobials is observed.

14 Although the increased incidence of infections caused by
 15 bacteria non-susceptible to antimicrobials is a challenge
 16 faced globally, newborns differ from other age groups due to
 17 their susceptibility to infections, clinical presentation, and
 18 high exposure to antimicrobials.⁴

19 One of the main strategies for controlling infections among
 20 the neonatal population consists of a better understanding of
 21 the risk factors and etiological agents, including the antimicro-
 22 bial resistance profile. The literature describes risk factors for
 23 colonization or infection by multidrug-resistant microorgan-
 24 isms.² However, systematic reviews may enhance the under-
 25 standing of the risk factors for the neonatal infections
 26 outbreaks caused by bacteria resistant to antimicrobials, so it
 27 is possible to develop specific coping strategies against the
 28 emergence and spread of these microorganisms.

29 This article describes a systematic review to evaluate
 30 studies related to outbreaks of resistant bacteria among
 31 patients in Neonatal Intensive Care Units (NICU), focusing on
 32 risk factors to understand the etiology and coping strategi-
 33 es.

34 Methods

35 The Preferred Reporting Items for Systematic Reviews and
 36 Meta-Analysis (PRISMA)⁵ were used to structure this system-
 37 atic review, which was registered with PROSPERO
 38 (CRD42023452888). The research question was defined as:
 39 “What are the risk factors in outbreaks of infection/coloni-
 40 zation by resistant microorganisms in Neonatal Units?”

41 The PECOS strategy was used, consisting of the
 42 components:

- 43 P - Neonatal population admitted to the Neonatal Inten-
 44 sive Care Unit
- 45 E - Risk factors for resistant bacterial infection
- 46 C - No risk factors for resistant bacterial infection
- 47 O - Isolation of resistant bacteria in an outbreak
- 48 S - Observational studies

49 Multidrug-Resistant Organisms are defined as bacteria
 50 resistant to one or more classes of antimicrobial agents

recommended for treatment (REF: CDC <https://www.cdc.gov/infection-control/hcp/mdro-management/background.html#toc>). 51
52
53

The search for studies occurred by consulting the 54
 PubMed, Embase, Cochrane, SciELO, and Scopus databases. 55

As descriptors, the terms were used: “Multiple drug resis- 56
 tance”, “Multiple bacterial drug resistance”, “Bacterial 57
 drug resistance”, “Microbial drug resistance”, “Infant, New- 58
 born”, “Disease outbreaks”, “Risk factors”. The search 59
 strategies are presented at Table 1. 60

The included studies were verified by two independent 61
 evaluators and met the following criteria: be published until 62
 June 2023; be available in any language; observe; and present 63
 a clinical observational research study. 64

To select publications, the title and abstract were ini- 65
 tially evaluated to confirm whether they addressed the 66
 research question and met the previously established inclu- 67
 sion criteria. If necessary, the study was read in full. 68

As exclusion criteria, studies were removed if the neona- 69
 tal population was not evaluated. Studies that did not pres- 70
 ent data necessary for extraction and analysis, or if there 71
 were duplicates were also removed. 72

For data extraction, a full analysis of the pre-selected 73
 studies was carried out by two independent researchers. Dis- 74
 crepancies were resolved by a third author. The extraction 75
 was compiled according to PRISMA,⁵ for subsequent analysis 76
 and qualitative evaluation of the studies. 77

For Meta-analysis, R language (4.3.3) was used. Data 78
 were transformed to a logarithmic scale to directly calculate 79
 the standard error from the confidence intervals. The evalu- 80
 ations were conducted using a random effects model, which 81
 uses the inverse variance method to define the weights. The 82
 Der Simonian-Laird estimator with Jackson’s method was 83
 used to estimate tau² values. The heterogeneity of the sam- 84
 ple is expressed in I², which is considered substantial when 85
 I² > 50%. Publication bias was assessed subjectively by fun- 86
 nel plots. 87

After data extraction, Critical Appraisal Tools recom- 88
 mended for cohorts and case-control studies by JBI⁶ scale 89
 was used to assess the quality of the articles analyzed. 90

Results 91

The initial search in the databases resulted in 496 studies: 92
 411 in Scopus, 50 in PubMed, 24 in Embase, nine in the 93
 Cochrane Library, and two in SciELO. From 496 studies, 48 94
 pre-selected studies were eligible for complete reading. 95
 According to the PECOS question, 21 articles were included 96
 in this systematic review, as presented in a flowchart in 97
 Figure 1. 98

There were 48 studies selected from which risk factor 99
 variables associated with outbreaks of multidrug-resistant 100
 bacteria in Neonatal Units were extracted. After complete 101
 reading, 21 articles were eligible for extraction and analysis 102
 (Table 2). 103

Table 1 Database search strategies for “Risk factors for colonization/infection by resistant microorganisms in a neonatal unit - a systematic review”.

PubMed	((Newborn OR infant OR neonatal OR neonates) AND (NICU OR "intensive care")) AND ((Resistance OR multiresistance OR resistant) AND (Multi-drug OR multidrug OR Antibiotic OR antimicrobials OR bacteria OR bacterial OR germs OR microbe)) AND (Outbreak). The filters used were: Clinical Study, Observational Study, Newborn: birth-1 month.
EMBASE	(newborn*exp OR newborn OR 'infant'/exp OR infant OR neonatal OR neonates) AND (nicu OR 'intensive care'exo OR 'intensive care' AND ['resistance'exo OR resistance OR multiresistance OR resistant) AND (multi drug OR multidrug OR 'antibiotic'/exp OR antibiotic OR 'antimicrobials'/exp OR antimicrobials OR "bacteria*exp OR bacteria OR bacterial OR germs OR 'microbe'/exp OR microbe AND ('outbreak'/exp OR outbreak) The filters used were: Humans, Clinical studies, Article.
SCIELO	((newborn) OR (neonatal) OR (infant)) AND ((Resistance) OR (multiresistance) OR (resistant)) AND ((Multi-drug) OR (multidrug) OR (Antibiotic) OR (antimicrobials) OR (bacteria) OR (bacterial) OR (germs) OR (microbe)) AND (Outbreak) AND ((Intensive care) OR (NICU)). No filters were used in this search.
COCHRANE	(newborn) OR (neonatal) OR (infant) in Title Abstract Keyword AND (Resistance) OR (multiresistance) OR (resistant) in Title Abstract Keyword AND outbreak in Title Abstract Keyword AND (Multi-drug) OR (multidrug) OR (Antibiotic) OR (antimicrobials) OR (bacteria) OR (bacterial) OR (germs) OR (microbe) in Title Abstract Keyword AND (Intensive care) OR (NICU) in Title Abstract Keyword - (Word variations have been searched). No filters were used in this search.
SCOPUS	(newborn OR neonates) AND (neonatal AND intensive AND care AND unity OR nicu) AND (resistance OR multiresistance OR resistant) AND (multi-drug OR multidrug OR antibiotic OR antimicrobials OR bacteria OR bacterial OR germs OR microbe) AND (outbreak) AND (LIMIT-TO (SUBJAREA, "MEDI")) AND (LIMIT-TO (EXACTKEYWORD, "Infant, Newborn")) AND (LIMIT-TO (DOCTYPE, "ar")) AND (LIMIT-TO (SRCTYPE, "j")). The filters used were Medicine, Article, Journal, Newborn.


**Figure 1** Flowchart of the Systematic Review - Assessment of Risk Factors for Outbreaks by Multiresistant Microorganisms in Neonatal Units (until 2023).

Table 2 Data extracted from the 21 eligible articles publish from 1980 to 2021.

First author (location, year)	Study design	Period of study	Hospitalized newborns	Outcome	Bacteria involved in the outbreak	Cases/ exposed	Controls/ not exposed	Significant risk factors	OR (95% CI)	P-value
Crellen et al. ^{2,6}	Cohort	09/2013-09/2014 (12 months)	333	Colonization	<i>Klebsiella pneumoniae</i> (3CG-R)	109	82	Use of Ampicillin + Gentamicin	1,96 (1,18-3,36)	-
Ulu-Kilic et al. ⁷	Case-control	07/2014-07/2015 (12 months)	149	Bloodstream infection	<i>Acinetobacter baumannii</i> (XDR-AB)	41	108	Gestational age (weeks)	-	0,028
Iosifidis et al. ²⁴	Case-control	06/2008-12/2008 (6 months)	389	Colonization	Vancomycin-resistant <i>Enterococcus faecium</i>	33 from 59	33 from 92	Peritoneal dialysis Mechanical ventilation Umbilical catheter Use of second-line antibiotics (glycopeptides, meropenem, ceftipime, astreosnam)	2,440 (1,101-5,410)	0,049 0,017 0,013 0,02
Cantey et al. ³	Cohort	04/2011-05/2011 (1 wk)	61	Infection/colonization	ESBL producing <i>Klebsiella pneumoniae</i>	11	50	Hospitalization period: Month 1 Month 3 Gestational age (weeks)	-	0,01 0,03 0,027
Rettedal et al. ⁸	Case-control	11/2008 - 04/2009 (5 months)	216	Colonization	<i>Klebsiella pneumoniae</i> (CTX-M-15-ESBL)	44	55	Birth weight Duration in days of use of humidified heated crib Duration in days of use of conventional crib Duration of use of umbilical venous catheter in days Duration of ventilatory support by ambient air in days Bedside surgical procedures Abdominal ultrasonography Use of surfactant Length of stay in the index patient's room Exposure in patient-days Mechanical ventilation	-	0,002 0,005 0,019 0,014 0,005 0,039 0,04 0,014 0,002 0,009 -
Guyot et al. ⁹	Case-control	02/2010 - 06/2010 (4 months)	263	Infection/colonization	ESBL producing <i>Klebsiella pneumoniae</i>	23	240	Use of CPAP Oxygen treatment Antibiotic treatment Indwelling bladder catheter Total parenteral nutrition Length of stay Gestational age < 37 wk Gestational age < 32 wk Use of Cefotaxime	5,6 (2,1 - 15,3) - - - - 7,6 (2,8 - 20,9) - -	- - 0,001 - - - -<0,001 0,04
Hosoglu et al. ¹⁰	Case-control	11/2006 - 08/2007 (9 months)	1.622 (em 2006)	Neonatal sepsis	<i>Acinetobacter baumannii</i> (MDR)	64	128	Use of Proton Pump Inhibitor Intubation Re-intubation Mechanical ventilation Total parenteral nutrition ICU length of stay (days) Birth weight	10,2 (4,8-21,6) - 12,8 (6,2-26,7) 7,5 (3,7-14,9) 4,4 (1,7-11,7) - -	<0,001 -<0,001 -<0,001 0,002 -<0,001 0,044 Outbreak 2*
Nguyen et al. ¹¹	Case-control	11/2003 - 06/2004 (7 months)	Not informed	Soft-tissue infection	<i>Staphylococcus aureus</i> (MRSA)	Outbreak 1: 5 1: 6 Outbreak 2: 24	Outbreak 1: 5 Outbreak 2: 22	Circumcision in the ward Use of injectable lidocaine Maternal age > 30 years	Outbreak 2* - - -	U** (1,7-U) U (2,6-U) U (2,1-U) -<0,01 -<0,01 -<0,01

Table 2 (Continued)

First author (location, year)	Study design	Period of study	Hospitalized newborns	Outcome	Bacteria involved in the outbreak	Cases/ exposed	Controls/ not exposed	Significant risk factors	OR (95% IC)	P-value							
Brito et al. ¹²	Case-control	10/2001 - 03/2002 (5 months)	33	Neonatal sepsis	<i>Acinetobacter baumannii</i> (MDR)	11	22	Birth weight: > 1500g	0,17 (0,02 - 1,03)	0,05							
								Age: > 7 days	0,08 (0,00 - 1,06)	0,03							
Khoury et al. ¹³	Case-control	10/2001-01/2002 (3 months)	28	Infection/ colonization	<i>Staphylococcus aureus</i> (MRSA)	12 infected 6 colonized	10	Duration of hospitalization (\geq 7 days)	26,67 (2,41 - 692,79)	<0,001							
								Antibiotic use	Indefinite	0,01							
								Use of carbapenems	<0,001	<0,001							
								Use of central venous catheter	17,50 (1,42-486,05)	<0,001							
								Mechanical ventilation	56,00 (4,07-1781,29)	<0,001							
								Daily prevalence of patients with MDR A. baumannii infection (%)	4,31 (1,46-13,00)	0,002							
								Risk factors for infection:									
								Multiple pregnancy	5,36 (1,37-20,96)	-							
								Gavage feeding	10,33 (1,28-83,37)	-							
								Intubation Age	5,97 (1,22-29,31)	-							
Average gestational	-	0,002															
Average birth weight	-	<0,01															
Average length of stay	-	0,003															
Risk factors for colonization:																	
Multiple gestation	37,5 (3,9-363,1)	-															
Mean gestational age	-	0,002															
Mean birth weight	-	<0,001															
Estimated gestational age	-	0,03															
Van der Zwet et al. ¹⁵	Case-control	09/1997 - 11/1997 (2 months)	Not informed	Infection/ colonization	ESBL-producing enterobacteriaceae (<i>Klebsiella pneumoniae</i> e <i>Escherichia coli</i>)	4	6	Duration of prior use of 3rd generation cephalosporin	-	0,02							
								None of the risk factors analyzed were statistically significant.	-	-							
Hedberg et al. ¹⁶	Case-control	07/1987 - 10/1987 (3 months)	146	Conjunctivitis	Gentamicin-resistant <i>Klebsiella pneumoniae</i> Erythromycin-resistant <i>Staphylococcus aureus</i>	8	16	Nurse A - initial care and bathing	9	0,01							
								Childbirth performed by Physician A Unit on the day of culture	2,7	0,03							
Balamohan et al. ¹⁷	Case-control	04/2017 - 03/2018 (11 months)	536	Colonization	<i>Staphylococcus aureus</i> (MRSA)	50	50	Respiratory support (invasive and non-invasive)	-	-0,0389							
								Ear test prior to MRSA colonization or control	-	0,0126							
								MRSA colonization pressure (%) during the week of new colonization or control	-	<0,0001							
								MRSA colonization pressure (%) during the week prior to new colonization or control	-	<0,0001							
								Surface ATP rate, week of colonization detection	-	0,0091							
Surface ATP rate, week prior to colonization detection	-	0,0128															

Table 2 (Continued)

First author (location, year)	Study design	Period of study	Hospitalized newborns	Outcome	Bacteria involved in the outbreak	Cases/ exposed	Controls/ not exposed	Significant risk factors	OR (95% CI)	P-value
Gajic et al. ¹⁸	Case-control	05/2018 - 07/2018 (2 months)	89	Neonatal sepsis	OXA-72-producing <i>Acinetobacter baumannii</i>	13	69	Gestational age (weeks)	-	0,033
Brown et al. ¹⁹	Case-control	2015 (54 days)	117	Infection/ colonization	<i>Staphylococcus aureus</i> (MRSA)	8	27	Type of delivery: Vaginal	-	0,018
								Cesarean section	-	-
								Apgar score at 1'	-	0,018
								Apgar score at 5'	-	0,016
								Mechanical ventilation	-	0,032
								Total parenteral nutrition	-	0,03
								Gestational age (days)	0,95/day (0,91-0,99)	0,001
								Birth weight (g)	0,997/g (0,994-0,9997)	<0,001
								Twin birth	7,30 (1,30-41)	0,02
								Nurse Exposure No. 007	7,33 (1,30-41)	0,02
								Nurse Exposure No. 033	5,75 (1,0-33)	0,049
								Nurse Exposure No. 035	15,60 (1,34-182)	0,02
								Nurse Exposure No. 045	-	<0,001
								Nurse Exposure No. 046	8,0 (1,28-50)	0,02
								Nurse Exposure No. 049	7,13 (1,17-43)	0,02
								Nurse Exposure No. 052	13,20 (2,03-86)	0,003
								Nurse Exposure No. 053	9,58 (1,61-57)	0,01
Nurse Exposure No. 068	20,83 (2,73-199)	0,001								
Nurse Exposure No. 107	7,33 (1,30-41)	0,02								
Nurse Exposure No. 116	8,57 (1,39-53)	0,01								
Nurse Exposure No. 118	5,83 (1,07-32)	0,04								
Nurse Exposure No. 137	40,25 (3,84-421)	<0,001								
Nurse Exposure No. 148	5,75 (1,0-33)	0,048								
Nurse Exposure No. 164	16,25 (1,75-158)	0,003								
Nurse Exposure No. 178	24,50 (2,50-240)	<0,001								
Nurse Exposure No. 180	12,50 (1,69-92)	0,01								
Nurse Exposure No. 192	5,83 (1,07-32)	0,04								
Gestational age (WHO categories):	3,68 (1,94-7,00)	<0,001								
Andersson et al. ²⁰	Case-control	12/2016-05/2017 (6 months)	91	Colonization	Vancomycin-resistant <i>Enterococcus</i> (VRE)	14	77	Extreme preterm	16,25 (3,79-62,62)	<0,001
								Gestational weight (categories):	2,68 (1,51-4,74)	0,001
								Very low weight	9,9 (1,31-74,73)	0,026
								Extreme low weight	14,14 (2,35-85,23)	0,004
								Resuscitation in Childbirth	2,37 (1,04-5,37)	0,039
								Intubation	7,1 (1,5-34,2)	0,014
								Respiratory Support:	-	-
								Ventilation	5,5 (1,45-21,24)	0,012
								CPAP	4,22 (1,28-13,99)	0,018
								High-Flow Oxygen	10,22 (1,53-68,23)	0,016
								With moisture	1,19 (1,09-1,30)	<0,001
								Total Parenteral Nutrition	5,52 (1,57-19,38)	0,008
								Central venous catheter	7,44 (2,17-25,46)	0,001
								Comorbidities:	-	-
								Infection with another organism	4,92 (1,47-16,43)	0,01
								Antibiotic therapy:	-	-
								Gentamicin	4,18 (1,08-16,15)	0,38
Ampicillin	6,73 (1,20-37,61)	0,03								
Flucloxacillin	6,47 (1,79-23,43)	0,004								
Nystatin Drops	10,8 (3,05-38,30)	<0,001								
Nystatin Cream	10,8 (3,05-38,30)	<0,001								
Antenatal Medication:	-	-								
Steroids	7 (1,85-26,46)	0,004								
Gestational weight	0,998 (0,997-0,999)	<0,001								

Table 2 (Continued)

First author (location, year)	Study design	Period of study	Hospitalized newborns	Outcome	Bacteria involved in the outbreak	Cases/exposed	Controls/not exposed	Significant risk factors	OR (95% IC)	P-value
Cheng et al. ²¹	Case-control	09/2017 - 02/2018 (6 months)	144	Infection/colonization	Community-associated <i>Staphylococcus aureus</i> (CA-MRSA)	15	131	Period of stay	1,04 (1,02-1,06)	<0,001
								Period of CPAP use	1,04 (1,02-1,06)	<0,001
								Period of incubator use	1,12 (1,04-1,09)	<0,001
								Period of use of umbilical venous catheter	1,33 (1,11-1,59)	<0,001
								Period of use of peripherally inserted central catheter	1,11 (1,03-1,20)	0,004
								Period of use of total parenteral nutrition	1,19 (1,02-1,39)	0,002
								Period of radiology use	1,15 (1,02-1,29)	0,18
								Cephalosporins	49,84 (3,10-810,6)	0,006
Zarrilli et al. ²²	Case-control	11/2010 - 07/2011 (8 months)	161	Infection/colonization	<i>Acinetobacter baumannii</i> (XDR)	22	139	Duration of hospitalization, in days	1,02 (1,00-1,04)	0,013
								Period of exposure to central venous catheter	5,2 (1,3-20,75)	0,019
Maragakis et al. ²³	Case-control	10/2004 - 02/2005 (4 months)	Not informed	Infection/colonization	<i>Serratia marcescens</i> (MDR)	16	32	Use of assisted ventilation	7,01 (1,3-37,88)	0,024
								Presence of arterial catheter	6,33 (1,50-26,7)	0,012
Mayhall et al. ²⁵	Case-control	04/1977 - 06/1978 (14 months)	Not informed	Infection/colonization	Gentamicin-resistant <i>Klebsiella pneumoniae</i> (GRKP)	18 infected 30 colonized	65	Receipt of inhalation therapy	7,22 (1,88-27,8)	0,004
								Nasopharyngeal suction	-	<0,001
								Nasogastric catheter for feeding	-	<0,001
								Ambu ventilation	-	<0,001
								Peripheral venous access	-	<0,01
								Prematurity	-	<0,01
								Umbilical Catheter	-	<0,05
								Gentamicin Therapy	-	<0,05

^aOnly outbreak 2 presented risk factors with statistical relevance (P -value < 0,05).

^bU, undefined.

104 It was found that, among the 21 articles selected, 19
105 were case-controls⁷⁻²⁵ and two were cohorts,³⁻²⁶ with the
106 study by Crellen et al.²⁶ being prospective and by Cantey et
107 al.³ retrospective.

108 Of the 21 studies analyzed, six studies were carried out in
109 developing countries: Turkey,⁷⁻¹⁰ Brazil,¹² Serbia,¹⁸ China,²¹
110 and Cambodia.²⁶ None of the studies analyzed carried out
111 multicenter evaluation. The other 15 studies were carried
112 out in developed countries: Norway,⁸ France,⁹
113 USA,^{3,11,13,14,16,17,23,25} Netherlands,¹⁵ United Kingdom,¹⁹
114 Australia,²⁰ Italy²² and Greece.²⁴

115 The studies covered the period between 1977 and 2018.
116 The follow-up time varied from seven days to 12 months,
117 with the longest time observed in studies from Turkey⁷ and
118 Cambodia.²⁶

119 The study population corresponded to all newborns
120 admitted to the NICU, regardless of weight or gestational
121 age. The studied population ranged from 10 to 263 new-
122 borns, with a total of 1979 newborns. The study carried out
123 in France was the largest in terms of population size.⁹
124 Regarding the number of patients hospitalized during the
125 studies, it ranged from 28 to 536, with a total of 2756 new-
126 borns. Six studies did not report the total population in the
127 Neonatal Unit during the period of the respective
128 studies.^{10,13,14,22,23,25}

129 Six studies evaluated infection,^{7,10,11,12,16,20} five evalu-
130 ated colonization^{8,17,20,24,26} and ten studies evaluated colo-
131 nization and infection.^{3,9,13,14,15,19,21,22,23,25}

132 Regarding the studies that evaluated risk factors for resis-
133 tant Gram-positive microorganisms, five studies evaluated
134 an outbreak due to MRSA,^{11,13,17,19,21} and one study evalu-
135 ated an outbreak due to *Staphylococcus aureus* resistant to
136 methicillin.¹⁷ Two studies evaluated vancomycin-resistant
137 *Enterococcus*.^{20,24} Regarding Gram-negative microorgan-
138 isms, five studies evaluated risk factors for *Acinetobacter*
139 *baumannii*, four of which defined multidrug-resistant
140 *Acinetobacter*^{7,10,12,22} and one of them included OXA-72-
141 producing *Acinetobacter baumannii*.¹⁸ Three studies evalu-
142 ated Neonatal Units in which ESBL (Extended Spectrum
143 Beta-Lactamases) producing *Klebsiella pneumoniae* was
144 isolated,^{3,11,14} and two studies included *Klebsiella pneumo-*
145 *niae* resistant to gentamicin.^{15,25} Furthermore, in one study,
146 newborns with *Klebsiella pneumoniae* resistant to third-gen-
147 eration cephalosporin²⁶ were included. One study evaluated
148 newborns in which ESBL-producing *Escherichia coli* was iso-
149 lated¹⁴ and another study included newborns with isolation
150 of multidrug-resistant *Serratia marcescens*.²³ It is notewor-
151 thy that one of the studies included the evaluation of two
152 microorganisms (ESBL-producing *K. pneumoniae* and *E. coli*)
153 in the analyzed outbreak.¹⁴

154 Nineteen of the 21 assessed gestational age,^{3,7-25} 18
155 assessed sex^{3,7-10,12,11-26} and 18 assessed birth weight.^{7,9-25}
156 Three studies analyzed maternal factors,^{3,11,17} two studies
157 evaluated the use of proton pump inhibitors^{3,9} and one study
158 evaluated the use of probiotics.²⁶ Other factors analyzed
159 were the use of: a central venous catheter,^{3,7,9,11,15,17,20,21,22}
160 umbilical catheter,^{3,7,10,15,18,22,25} mechanical ventilation,<sup>3,7-
161 10,12,15,18,20-22,24</sup> continuous positive airways pressure
162 (CPAP),^{3,8,9,20} parenteral nutrition.^{3,7,8,10,18,20,21,24} Further-
163 more, race,^{17,23} period of hospitalization^{3,10,11,13-15,22,23,24}
164 and type of delivery^{8,11,16,18,20} were evaluated.

165 Of the 19 studies that analyzed Gestational Age (GA),
166 nine had this variable with statistical relevance, with
167 $p < 0,05$,^{3,7-9,13,14,18-20} and the largest one demonstrated
168 more than seven times greater chance of colonization in
169 newborns with < 37 wk of GA.⁸

170 Eighteen studies analyzed the gender variable, but none
171 achieved statistical significance. The same number of
172 articles also analyzed birth weight and only six showed sig-
173 nificance, associating lower weight with a higher risk of
174 infection.^{3,9,12,13,19,20}

175 Twelve studies analyzed mechanical ventilation as a pre-
176 dictor and eight had statistical significance,^{3,7,8,10,12,18,20,22}
177 and one of them showed a more than seven times greater
178 chance of infection in patients with mechanical ventila-
179 tion.¹⁰ Seven articles highlighted the period of
180 hospitalization,^{3,8,10,11,12,13,21} the largest of which demon-
181 strated approximately 26 times greater chance of infection
182 in newborns with >7 days of hospitalization.¹²

183 Among the eight articles that analyzed parenteral nutri-
184 tion, two articles were able to associate its use with
185 infection^{10,18} and two with colonization,^{8,20} with statistical
186 significance reaching four times greater chance.¹⁰ Seven
187 studies were dedicated to evaluating the use of umbilical
188 catheters associated with infection/colonization, three
189 obtained significant results.^{3,7,25} There were still three stud-
190 ies that achieved significance by associating intubation with
191 neonatal infection/colonization,^{3,7,25} the largest one dem-
192 onstrated an increased chance of infection by > 10 times.¹⁰

193 Nine articles analyzed the use of central venous catheters
194 (CVC), and three of them achieved statistical
195 significance,^{12,20,21} the largest one presenting 56 times
196 greater chance of infection in newborns with CVC.¹²

197 Regarding the use of antimicrobials, a great heterogene-
198 ity was observed. Fifteen of them assessed the use of antimi-
199 crobials as a categorized variable and a greater chance of
200 infection/colonization was observed in nine of
201 them.^{8,9,12,14,20,21,24,25,26} Eight studies evaluated specific
202 classes of antimicrobials.^{9,12,14,20,21,24,25,26} Gentamicin was
203 evaluated by Andersson et al.²⁰ and by Mayhall et al.,²⁵
204 while cephalosporins were included in studies by Linkin
205 et al.¹⁴ and by Cheng et al.²¹ The most significant study asso-
206 ciated Cephalosporins with infection/colonization, achiev-
207 ing >49 times greater chance with their use.²¹ Other studies
208 also achieved statistically significant results associating Car-
209 bapenems with a 17 times greater chance of infection/colo-
210 nization.¹² Gentamicin was associated with a six times
211 greater chance of infection by a resistant microorganism,
212 while nystatin had a 10 times greater chance of the same
213 outcome occurring.²⁰ A study evaluated Flucloxacillin and
214 found a six times greater chance of colonization with its
215 use.²⁰ Two studies analyzed the use of antibiotics without
216 class specification,^{10,12} with a significative association
217 between ATB use and a five times greater chance of infec-
218 tion/colonization.¹⁰

219 Only one study²⁶ considered protective factors in the
220 analysis, however, none of them presented variables statisti-
221 cally significant associated with the reduction of infection/
222 colonization by resistant bacteria.

223 The quality assessment of the studies was carried out
224 according to the recommendations of the JBI Critical
225 Appraisal Tools.⁶

Of the total of 21 studies, two had a cohort design and 19 were case-control studies. All the 21 articles were included in this systematic review. Regarding the case-control studies, all the studies received “yes” for the first, fifth, eighth, ninth, and tenth checklist items. Seven studies did not assure the second item, because it was not possible to identify any pairing method in the text.^{14,18-23} Only one study did not clearly mention if the controls were defined as patients with negative bacterial cultures, which were defined as asymptomatic patients. Thus, “no” was considered for the third checklist item.¹¹ The fourth item was not assured by one study, because it was not possible to find in the text objective information about the source of the patients’ data.¹³ Regarding the sixth item, seven studies did not identify any possible bias or confounding factors,^{7,9,12,21,22,23,25} but Iosifidis et al. mentioned a limitation of the study that could not clearly play the role of confounding factor. For this same reason, Iosifidis et al. received “unclear” for the seventh item. Another study also received “unclear” for this item, because, although it has described confounding factors, it was difficult to affirm the description of ways to deal with the problem.¹⁶ Fifteen studies did not mention any kind of strategy required in the seventh item.^{7,9-14,17-23,25} In relation to cohort studies, almost all the items were fulfilled by both analyzed, except for the fact that Cantey et al. did not describe confounding factors or strategies to deal with them (fourth and fifth items) and for the tenth item, considering that there was not incomplete follow up in any of the studies. The quality evaluation is presented in Table 3.

Meta-analysis was carried out for the same and well-defined study variables that were included in more than one study. Three variables presented a significantly higher chance of colonization or infection with multidrug-resistant bacteria: (a) use of venous access (OR 1.58; 95%CI 1.14 - 2.20); (b) use of mechanical ventilation (OR 7.55; CI95 % 4.27 - 13.36); (c) use of parenteral nutrition (OR 4.79; CI95 % 2.23 - 10.29). The studies showed low heterogeneity in the use of mechanical ventilation and parenteral nutrition, both with $I^2 = 0\%$. However, heterogeneity was significant regarding the use of venous access ($I^2 = 75\%$) (Figures 2 and 3).

Discussion

The main risk factors for infection/colonization by antimicrobial-resistant bacteria in NICU outbreaks were Mechanical Ventilation, Venous Access, and Parenteral Nutrition also identified in other reviews that were not focused on outbreaks.^{27,28}

The temporal range of this analysis made it possible to include a greater number of patients, representing neonatal populations from different countries. It is noteworthy that over more than three decades, there have been changes in the care and structure of Neonatal Units, with a focus on reducing neonatal mortality.²⁹

Early detection of outbreaks and the prompt application of preventive measures can help define research priorities and develop integrated prevention strategies for these microorganisms in the NICU.^{1,30}

There was a wide variation in population size between studies, however, it is important to highlight that even the

lower numbers of recorded infections/colonization by resistant microorganisms should also be treated as relevant in the neonatal population. Newborns have immunological immaturity, which favors invasive infections by these microorganisms.³¹ Therefore, identifying risk factors is relevant for the prevention and control of these infections especially when there is colonization by these pathogenic microorganisms.²⁹

Colonization by resistant bacteria should also be considered as a risk factor for infection in neonates.² Cantey et al.³ demonstrated greater lethality of infections in neonatal ICU patients infected or colonized by ESBL-producing *Klebsiella pneumoniae*, compared to patients infected by non-resistant bacteria. A study carried out in Jordan in 2017 also demonstrated a significant difference between the mortality rates of neonatal sepsis due to sepsis by resistant microorganisms compared to those with non-resistant microorganisms.²⁹

Regarding the characteristics of the bacteria involved in the outbreaks reported by the selected studies, most studies included outbreaks due to Gram-negative bacteria. In developed countries, the main pathogens causing early neonatal sepsis are Gram-positive (group B Streptococcus) in full-term patients, while *E. coli*, a Gram-negative bacterium, is the most common microorganism among preterm infants with early-onset neonatal sepsis. Regarding late-onset neonatal sepsis, 15 to 30% of cases are caused by *E. coli* or *Klebsiella species*.² In very low birth weight newborns, coagulase-negative *Staphylococcus* predominates as an etiological agent of late neonatal sepsis in patients using invasive devices.³² Multicenter Chinese and Brazilian studies revealed that more than half of cases of late neonatal sepsis present Gram-negative bacteria as etiological agents in these countries, with emphasis on the order of *Enterobacteriales*.^{33,34} Recent evidence has shown an increase in the number of neonatal infections caused by Gram-negative bacteria resistant to multiple drugs. These microorganisms are species commonly identified in neonatal sepsis, with an increasing resistance to antimicrobials. This fact demonstrates the need to optimize the use of antimicrobials in the management of neonatal infections.^{2,35,36}

Approximately, one-third of the eligible studies included Gram-positive bacteria as responsible for outbreaks. The literature demonstrates that *Staphylococcus* is significantly related to late-onset neonatal sepsis and antimicrobial resistance, mainly in isolates from patients undergoing mechanical ventilation, according to extracted data from the works in this review.^{13,17,35-37}

The use of broad-spectrum antibiotics favors the multiplication of resistant microorganisms and predisposes patients to colonization/infection by these agents. ESBL-producing bacteria, for example, are combated by carbapenems, a group of antimicrobials that have been identified as a risk factor for colonization/infection by bacteria with antimicrobial resistance.¹²

The use of antimicrobials was also evaluated, with emphasis on the most used to treat early neonatal sepsis (ampicillin and gentamicin) and cephalosporins, but great heterogeneity difficulted meta-analysis. Antimicrobials are essential for timely and adequate therapy for newborn infections, however, it is necessary to consider that these medications may modify microbiota, lead to adverse

Table 3 Assessment of the quality of studies using the JBI Critical Appraisal Tools recommended for cohorts and case-control studies.

Checklist case control studies												
First author (local, year)	1- Were the groups comparable other than the presence of disease in cases or the absence of disease in controls?	2- Were cases and controls matched appropriately?	3- Were the same criteria used for identification of cases and controls?	4- Was exposure measured in a standard, valid and reliable way?	5- Was exposure measured in the same way for cases and controls?	6- Were confounding factors identified?	7- Were strategies to deal with confounding factors stated?	8- Were outcomes assessed in a standard, valid and reliable way for cases and controls?	9- Was the exposure period of interest long enough to be meaningful?	10- Was appropriate statistical analysis used?	Overall appraisal	
Iosifidis et al. ²⁴	Yes	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	Yes	Yes	Include	
Ulu-Kilitic et al. ⁷	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Rettedal et al. ⁸	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Include	
Guyot et al. ⁹	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Hosoglu et al. ¹⁰	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Nguyen et al. ¹¹	Yes	Yes	Unclear	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Brito et al. ¹²	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Khoury et al. ¹³	Yes	Yes	Yes	Unclear	Yes	Yes	No	Yes	Yes	Yes	Include	
Linkin et al. ¹⁴	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Van der Zwet et al. ¹⁵	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Include	
Hedberg et al. ¹⁶	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Include	
Balamohan et al. ¹⁷	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Gajic et al. ¹⁸	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Andersson et al. ²⁰	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Zarrilli et al. ²²	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Mayhall et al. ²⁵	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Brown et al. ¹⁹	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Include	
Cheng et al. ²¹	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Maragakis et al. ²³	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Include	
Checklist cohort studies												
First author (local, year)	1- Were the two groups similar and recruited from the same population?	2- Were the exposures measured similarly to assign people to both exposed and unexposed groups?	3- Was the exposure measured in a valid and reliable way?	4- Were confounding factors identified?	5- Were strategies to deal with confounding factors stated?	6- Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)?	7- Were the outcomes measured in a valid and reliable way?	8- Was the follow up time reported and sufficient to be long enough for outcomes to occur?	9- Was follow up complete, and if not, were the reasons to loss to follow up described and explored?	10- Were strategies to address incomplete follow up utilized?	11- Was appropriate statistical analysis used?	Overall appraisal
Crellen et al. ²⁶	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Include
Cantey et al. ³	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Include




Figure 2 Meta-analysis for variables associated to colonization/infection by resistant microorganisms in outbreaks in Neonatal Units. (a) Use of venous access (b) Use of mechanical ventilation (c) Use of parenteral nutrition.

347 reactions, and develop antimicrobial resistance.³⁸ There-
 348 fore, the importance of institutional programs that aim for
 349 the rational use of antibiotics in the neonatal population is
 350 necessary.³⁵ Several authors have studied interventions to
 351 optimize the prescription of antimicrobials in different
 352 countries.³⁹ In Sweden, demonstrated a benefit in choosing
 353 treatments of shorter duration with the support of the infec-
 354 tious diseases consultancy service, resulting in reduced use
 355 of meropenem-based therapy in extremely premature
 356 infants, without increasing the mortality or the need to
 357 restart treatment.⁴⁰ In the present review, ampicillin, asso-
 358 ciated with gentamicin, was identified as a risk factor for
 359 colonization by resistant bacteria,²⁶ and a study carried out
 360 in the USA demonstrated a significantly decreased use of
 361 ampicillin after the application of strategies, such as the
 362 education of multidisciplinary teams, with development of
 363 protocols on the approach to common neonatal infections.⁴¹
 364 A study carried out in Brazil, demonstrated a similar result,
 365 with the application of the National Health Surveillance
 366 Agency criteria as a diagnostic tool for early neonatal sepsis
 367 reducing the number of diagnoses of this disease and the use
 368 of antimicrobials for early neonatal sepsis. There was also a
 369 reduction in general mortality and mortality related to
 370 infections after this intervention.⁴² The adoption of epi-
 371 demiological surveillance systems for neonatal sepsis was iden-
 372 tified as a contributing factor to reducing the excessive use
 373 of antibiotics in a study carried out in Spain.³²

374 Although not all studies have found statistical relevance
 375 for preterm birth or low birth weight, these conditions can

376 be associated with other situations that predispose new-
 377 borns to infections, such as invasive devices (central venous
 378 catheter, umbilical catheter, mechanical ventilation) and
 379 parenteral nutrition. These devices facilitate adherence and
 380 hematogenous entry for potentially pathogenic microorgan-
 381 isms, predisposing newborns to HAIs.^{1,29,32,43}

382 Protective factors against colonization/infection by mul-
 383 tidrug-resistant bacteria were evaluated in only one of the
 384 selected studies, which did not find statistical relevance in
 385 any of the factors analyzed.²⁶ However, it is noteworthy that
 386 most studies pointed to optimizing the hand washing tech-
 387 nique of professionals in NICU as important for controlling
 388 outbreaks of multi-resistant bacteria. Horizontal transmis-
 389 sion by hand has been described as the main source of post-
 390 natal infection in newborns admitted to hospitals.³⁰ Thus, it
 391 reinforces the necessity of correct hand hygiene in the five
 392 moments recommended by the WHO before and after new-
 393 born assistance.⁴⁴ Nguyen et al.¹¹ Demonstrated that the
 394 transmission of methicillin-resistant *Staphylococcus aureus*
 395 (MRSA) was probably facilitated by inadequate hand hygiene
 396 practices. Rettedal et al.⁸ highlighted correct hand washing
 397 as the single most crucial factor in reducing the rates of nos-
 398 ocomial infections, besides, it is the least expensive infec-
 399 tion control technique applied in the NICU.

400 The main risk factor identified as associated with multi-
 401 resistant microorganisms in outbreaks in NICU (Mechanical
 402 Ventilation, followed by Parenteral Nutrition and Venous
 403 Access), which are frequently used in NICU once these are
 404 required for assistance of preterm newborns and those with




Figure 3 Funnel plot to access publication bias.

malformations, mainly those who require gastrointestinal surgery.^{45,46} For premature infants, the use of Continuous Positive Airway Pressure (CPAP) and other non-invasive ventilation used for both initial and post-intubation with timely removal of tracheal cannula may minimize the risk of lung disease and, consequently, reduce risk of infection.^{47,48} Adequacy of early and optimized Parenteral Nutrition can reduce the time of CVC use with this proposal,⁴⁹ and bundles for the prevention of CVC-associated infections are also mandatory.⁵⁰ The early human milk diet also reduces the time of parenteral nutrition and late-onset sepsis in newborns.⁵¹ Recommendations for safe surgeries and adequate preoperative prophylaxis are international policies for the prevention of infection in these patients.^{45,52}

Although this review was restricted to the research question, it was directed to investigate risk factors in outbreaks, which were not identified in other studies. Several reviews included a larger number of studies that evaluated risk factors for infection in neonates despite this objective.

Thus, the best current tool for combating neonatal infections is prevention, mainly with hand hygiene practices.^{35,44} Other practices for controlling infections identified in outbreaks include the use of personal protective equipment, respiratory hygiene, patient placement and private rooms according to the transmission route, patient-care equipment and devices, and care of the environment with cleaning/disinfection.^{2,53}

Despite the studies did not meet all the criteria according to the JBI Critical Appraisal Tools recommended for cohorts and case-control studies,⁶ they were included and considered as having the good quality to trust the meta-analysis results, which allows actions directed to prevent these infections.

439 Conclusion

The main risk factors for infection/colonization by antimicrobial-resistant bacteria among patients admitted to NICU are the use of invasive devices such as Mechanical Ventilation, Venous Access, and Parenteral Nutrition. The best current tool is the prevention of neonatal infections, which can be achieved mainly through compliance with hand hygiene to manipulate neonates and their devices and the adoption of measures for the timely withdrawal of these interventions.

449 Conflicts of interest

450 The authors declare no conflicts of interest.

451 Financial support

452 This work was supported by the Federal University of Minas Gerais (Pró-reitoria de Pesquisa) and National Council for Scientific and Technological Development (CNPq) Brazil, through the Institutional Scientific Initiation Scholarships (Volunteers and PIBIC), and by Minas Gerais State Agency for Research and Development (FAPEMIG).

References

1. Agência Nacional de Vigilância Sanitária - Anvisa. Caderno 3 - Critérios Diagnósticos de Infecção Associada à Assistência à Saúde Neonatologia. 2017 [Accessed January 8, 2024]. Available from: <https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/publicacoes/caderno-3-criterios-diagnosticos-de-infeccao-associada-a-assistencia-a-saude-neonatalogia.pdf/view>
2. Flannery DD, Chiotos K, Gerber JS, Puopolo KM. Neonatal multi-drug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management. *Pediatr Res.* 2022;91:380–91.
3. Cantey JB, Sreeramaju P, Jaleel M, Treviño S, Gander R, Hynan LS, et al. Prompt control of an outbreak caused by extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit. *J Pediatr.* 2013;163:672-9.e1-3.
4. Katz S, Banerjee R, Schwenk H. Antibiotic stewardship for the neonatologist and perinatologist. *Clin Perinatol.* 2021;48:379–91.
5. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;6:e1000100.
6. JBI. Critical appraisal tools. [Accessed November 7, 2024]. Available from: <https://jbi.global/critical-appraisal-tools>.
7. Ulu-Kilic A, Gundogdu A, Cevahir F, Kilic H, Gunes T, Alp E. An outbreak of bloodstream infection due to extensively resistant *Acinetobacter baumannii* among neonates. *Am J Infect Control.* 2017;46:154–8.
8. Rettedal S, Löhr IH, Natås O, Sundsfjord A, Øymar K. Risk factors for acquisition of CTX-M-15 extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* during an outbreak in a neonatal intensive care unit in Norway. *Scand J Infect Dis.* 2013;45:54–8.
9. Guyot K, Biran V, Doit C, Moissenet D, Guillard T, Brasme L, et al. Raman spectroscopic analysis of the clonal and horizontal spread of CTX-M-15-producing *Klebsiella pneumoniae* in a neonatal intensive care unit. *Eur J Clin Microbiol Infect Dis.* 2012;31:2827–34.
10. Hosoglu S, Hascuhadar M, Yasar E, Uslu S, Aldudak B. Control of an *Acinetobacter* [corrected] *baumannii* outbreak in a neonatal ICU without suspension of service: a devastating outbreak in Diyarbakir, Turkey. *Infection.* 2012;40:11–8.
11. Nguyen DM, Bancroft E, Mascola L, Guevara R, Yasuda L. Risk factors for neonatal methicillin-resistant *Staphylococcus aureus* infection in a well- infant nursery. *Infect Control Hosp Epidemiol.* 2007;28:406–11.
12. Brito DV, Oliveira EJ, VO Abdallah, da Costa, Darini AL, Filho PP. An outbreak of *Acinetobacter baumannii* septicemia in a neonatal intensive care unit of a university hospital in Brazil. *Braz J Infect Dis.* 2005;9:301–9.
13. Khoury J, Jones M, Grim A, Dunne M, Fraser V. Eradication of methicillin-resistant *Staphylococcus aureus* from a neonatal intensive care unit by active surveillance and aggressive infection control measures. *Infect Control Hosp Epidemiol.* 2005;26:616–21.
14. Linkin DR, Fishman NO, Patel JB, Merrill JD, Lautenbach E. Risk factors for extended-spectrum beta-Lactamase-producing enterobacteriaceae in a neonatal intensive care unit. *Infect Control Hosp Epidemiol.* 2004;25:781–3.
15. Van der Zwet WC, Parlevliet GA, Savelkoul PH, Stoof J, Kaiser AM, Koeleman JG, et al. Nosocomial outbreak of gentamicin-resistant *Klebsiella pneumoniae* in a neonatal intensive care unit controlled by a change in antibiotic policy. *J Hosp Infect.* 1999;42:295–302.

- 525 16. Hedberg K, Ristinen TL, Soler JT, White KE, Hedberg CW, Oster-
526 holm MT, et al. Outbreak of erythromycin-resistant staphylococ-
527 cal conjunctivitis in a newborn nursery. *Pediatr Infect Dis J*.
528 1990;9:268–73.
- 529 17. Balamohan A, Beachy J, Kohn N, Rubin LG. Risk factors for noso-
530 comial methicillin resistant *Staphylococcus aureus* (MRSA) colo-
531 nization in a neonatal intensive care unit: a case-control study.
532 *Am J Infect Control*. 2021;49:1408–13.
- 533 18. Gajic I, Jovicevic M, Milic M, Kekic D, Opavski N, Zrnica Z, et al.
534 Clinical and molecular characteristics of OXA-72-producing *Acin-*
535 *tobacter baumannii* ST636 outbreak at a neonatal intensive
536 care unit in Serbia. *J Hosp Infect*. 2021;112:54–60.
- 537 19. Brown NM, Reacher M, Rice W, Roddick I, Reeve L, Verlander
538 NQ, et al. An outbreak of methicillin-resistant *Staphylococcus*
539 *aureus* colonization in a neonatal intensive care unit: use of a
540 case-control study to investigate and control it and lessons
541 learnt. *J Hosp Infect*. 2019;103:35–43.
- 542 20. Andersson P, Beckingham W, Gorrie CL, Kennedy K, Daveson K,
543 Ballard SA, et al. Vancomycin-resistant *Enterococcus* (VRE) out-
544 break in a neonatal intensive care unit and special care nursery
545 at a tertiary-care hospital in Australia-A retrospective case-con-
546 trol study. *Infect Control Hosp Epidemiol*. 2019;40:551–8.
- 547 21. Cheng VC, Wong SC, Cao H, Chen JH, So SY, Wong SC, et al.
548 Whole-genome sequencing data-based modeling for the investi-
549 gation of an outbreak of community-associated methicillin-
550 resistant *Staphylococcus aureus* in a neonatal intensive care
551 unit in Hong Kong. *Eur J Clin Microbiol Infect Dis*.
552 2019;38:563–73.
- 553 22. Zarrilli R, Di Popolo A, Bagattini M, Giannouli M, Martino D,
554 Barchitta M, et al. Clonal spread and patient risk factors for
555 acquisition of extensively drug-resistant *Acinetobacter bau-*
556 *mannii* in a neonatal intensive care unit in Italy. *J Hosp Infect*.
557 2012;82:260–5.
- 558 23. Maragakis LL, Winkler A, Tucker MG, Cosgrove SE, Ross T, Law-
559 son E, et al. Outbreak of multidrug-resistant *Serratia marces-*
560 *cens* infection in a neonatal intensive care unit. *Infect Control*
561 *Hosp Epidemiol*. 2008;29:418–23.
- 562 24. Iosifidis E, Evdoridou I, Agakidou E, Chochliourou E, Protonota-
563 riou E, Karakoula K, et al. Vancomycin-resistant *Enterococcus*
564 outbreak in a neonatal intensive care unit: epidemiology,
565 molecular analysis and risk factors. *Am J Infect Control*.
566 2013;41:857–61.
- 567 25. Mayhall CG, Lamb VA, Bitar CM, Miller KB, Furse EY, Kirkpatrick
568 BV, et al. Nosocomial klebsiella infection in a neonatal unit:
569 identification of risk factors for gastrointestinal colonization.
570 *Infect Control*. 1980;1:239–46.
- 571 26. Crellen T, Turner P, Pol S, Baker S, Nguyen Thi, Nguyen T,
572 Stoesser N, et al. Transmission dynamics and control of multi-
573 drug-resistant *Klebsiella pneumoniae* in neonates in a develop-
574 ing country. *Elife*. 2019;8:e50468.
- 575 27. Araújo BC, Guimarães H. Risk factors for neonatal sepsis: an
576 overview. *J Pediatr Neonat Individual Med*. 2020;9:e090206.
- 577 28. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlap-
578 bach LJ, Reinhart K, Kisssoon N. The global burden of paediatric
579 and neonatal sepsis: a systematic review. *Lancet Respir Med*.
580 2018;6:223230.
- 581 29. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. *Lancet*.
582 2017;390:1770–80.
- 583 30. Chan GJ, Lee AC, Baqui AH, Tan J, Black RE. Risk of early-onset
584 neonatal infection with maternal infection or colonization: a
585 global systematic review and meta-analysis. *PLoS Med*.
586 2013;10:e1001502.
- 587 31. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and limitations of
588 the neonatal immune system. *Front Pediatr*. 2020;8:5.
- 589 32. Estañ-Capell J, Alarcón-Torres B, Bermúdez JD, Martínez-Rodríguez
590 L, Martínez-Costa C. Effect of a surveillance system for
591 decreasing neonatal nosocomial infections. *Early Hum Dev*.
592 2019;131:36–40.
- 593 33. Jiang S, Yang C, Yan W, Shah V, Shah PS, et al. Epidemiology
594 and microbiology of late-onset sepsis among preterm
595 infants in China, 2015-2018: a cohort study. *Int J Infect Dis*.
596 2020;96:1–9.
- 597 34. Couto RC, Carvalho EA, Pedrosa TM, Pedrosa ER, Neto MC, Bis-
598 cione FM. A 10-year prospective surveillance of nosocomial
599 infections in neonatal intensive care units. *Am J Infect Control*.
600 2007;35:183–9.
- 601 35. Dong Y, Speer CP. Late-onset neonatal sepsis: recent develop-
602 ments. *Arch Dis Child Fetal Neonatal Ed*. 2015;100:F257–63.
- 603 36. Cantey JB, Milstone AM. Bloodstream infections: epidemiology
604 and resistance. *Clin Perinatol*. 2015;42:1–16.
- 605 37. Alarjani KM, Almutairi AM, AlQahtany FS, Soundharrajan I.
606 Methicillin and multidrug resistant pathogenic *Staphylococcus*
607 *aureus* associated sepsis in hospitalized neonatal infections and
608 antibiotic susceptibility. *JIPH*. 2021;14:1630–4.
- 609 38. McPherson C, Liviskie C, Zeller B, Nelson MP, Newland JG. Anti-
610 microbial stewardship in neonates: challenges and opportuni-
611 ties. *Neonatal Netw*. 2018;37:116–23.
- 612 39. Lima DM, Resende RV, Diniz LM, Anchieta LM, Romanelli RM.
613 Evaluation of antimicrobial consumption in the neonatal popu-
614 lation undergoing antimicrobial stewardship programmes: a sys-
615 tematic review. *J Hosp Infect*. 2023;135:106–18.
- 616 40. Gustavsson L, Lindquist S, Elfvin A, Hentz E, Studahl M. Reduced
617 antibiotic use in extremely preterm infants with an antimicro-
618 bial stewardship intervention. *BMJ Paediatr Open*. 2020;4:
619 e000872.
- 620 41. Nzegwu NI, Rychalsky MR, Nallu LA, Song X, Deng Y, Natusch AM,
621 et al. Implementation of an antimicrobial stewardship program
622 in a neonatal intensive care unit. *Infect Control Hosp Epidemiol*.
623 2017;38:1137–43.
- 624 42. Pinto MC, Bueno AC, Vieira AA. Implementation of a protocol
625 proposed by the Brazilian National Health Surveillance Agency
626 for antibiotic use in very low birth weight infants. *J Pediatr* (Rio
627 J). 2013;89:450–5.
- 628 43. Romanelli RM, Anchieta LM, Mourão MV, Campos FA, Loyola FC,
629 Mourão PH, et al. Risk factors and lethality of laboratory-con-
630 firmed bloodstream infection caused by non-skin contaminant
631 pathogens in neonates. *J Pediatr* (Rio J). 2013;89:189–96.
- 632 44. World Health Organization. Hand Hygiene: Why, How & When?
633 Geneva: WHO; 2024. [Accessed July 14, 2024]. Available from:
634 <https://cdn.who.int/media/docs/default-source/documents/health-topics/hand-hygiene-why-how-and-when-brochure.pdf>.
- 635 45. Catania VD, Boscarelli A, Laurittu G, Morini F, Zani A. Risk fac-
636 tors for surgical site infection in neonates: a systematic
637 review of the literature and meta-analysis. *Front Pediatr*.
638 2019;7:1–11.
- 639 46. Romanelli RM, Anchieta LM, Carvalho EA, Silva LF, Nunes RV,
640 Mourão PH, et al. Risk factors for laboratory-confirmed blood-
641 stream infection in neonates undergoing surgical procedures.
642 *Braz J Infect Dis*. 2014;18:400–5.
- 643 47. Subramaniam P, Ho JJ, Davis PG. Prophylactic or very early initi-
644 ation of continuous positive airway pressure (CPAP) for preterm
645 infants. *Cochrane Datab System Rev*. 2021. [Accessed June 22,
646 2024]. Available: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001243.pub4/full>.
- 647 48. Bondarev DJ, Ryan RM, Mukherjee D. The spectrum of pneumo-
648 nia among intubated neonates in the neonatal intensive care
649 unit. *J Perinatol*. 2024;44:1235–43.
- 650 49. Smazal AL, Ilahi IM, Raucci J, Robinson D. Administering paren-
651 teral nutrition in the neonatal intensive care unit: logistics,
652 existing challenges, and a few conundrums. *Clin Perinatol*.
653 2023;50:557–73.
- 654 50. Bruant K., Brady M.T., Myers K., Fauerbach L.L., Guzman-Cot-
655 trill Hogges J et al. Center for Diseases Control and Prevention
656 (CDC). National Center for Emerging and Zoonotic Infectious
657 Diseases. Division of Healthcare Quality Promotion. Guideline
658 for Prevention of Infections in Neonatal Intensive Care Unit
659
660

- 661 Patients Recommendations for Prevention and Control of Infec- 671
662 tions in Neonatal Intensive Care Unit Patients: Central Line- 672
663 associated Blood Stream Infections 2022 [Accessed June 22, 673
664 2024]. Available: [https://www.cdc.gov/infection-control/](https://www.cdc.gov/infection-control/media/pdfs/Guideline-NICU-CLABSI-508.pdf) 674
665 [media/pdfs/Guideline-NICU-CLABSI-508.pdf](https://www.cdc.gov/infection-control/media/pdfs/Guideline-NICU-CLABSI-508.pdf). 675
- 666 51. Coyne R, Hughes W, Purtill H, McGrath D, Dunne C, Phillip RK. 676
667 Influence of an early human milk diet on the duration of paren- 677
668 teral nutrition and incidence of late-onset sepsis in very low 678
669 birthweight (VLBW) infants: a systematic review. *Breastfeed* 679
670 *Med.* 2024;19:425–34.
- 671 52. Guidelines For Safe surgery: Safe Surgery Saves Lives. Would 672
672 Health Organization (WHO); 2024, Accessed April 16, Available 673
673 from: [https://www.who.int/publications/i/item/9789241598](https://www.who.int/publications/i/item/9789241598552) 674
674 [552](https://www.who.int/publications/i/item/9789241598552). 675
- 675 53. Isolation Prevention Guidelines. Summary of Recommendations. 676
676 Center for Diseases Control and Prevention; 2023, [Accessed 677
677 October 31, 2024]. Available: [https://www.cdc.gov/infection-](https://www.cdc.gov/infection-control/hcp/isolation-precautions/summary-recommendations.html) 678
678 [control/hcp/isolation-precautions/summary-recommenda-](https://www.cdc.gov/infection-control/hcp/isolation-precautions/summary-recommendations.html) 679
679 [tions.html](https://www.cdc.gov/infection-control/hcp/isolation-precautions/summary-recommendations.html). 679